RxDoctor Payments Data

Paul Larsen, MD

Family Medicine · Chewelah, WANPI 1720189749

Payments from drug & device makers

$1,276in general payments, 2019–2025

Across 89 payments — averaging $14.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$167
  • Novo Nordisk$155
  • Pfizer$144
  • Boehringer Ingelheim$140
  • Sanofi-aventis U.S. LLC$137
  • AstraZeneca$135
  • plus $398 from 12 others

What the payments were for

  • Food & beverage$1,25899%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,276 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$6,770
Medicare patients
132
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl54$67,710
EliquisApixaban69$53,371
OzempicSemaglutide48$42,065
JardianceEmpagliflozin54$36,686
XareltoRivaroxaban31$34,618
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog69$33,894
TrulicityDulaglutide33$33,631
Tresiba Flextouch U-200Insulin Degludec15$27,738
FarxigaDapagliflozin Propanediol37$27,334
VraylarCariprazine Hcl16$21,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,348
Repatha SureclickEvolocumab25$19,797
RybelsusSemaglutide16$15,018
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,174
TradjentaLinagliptin13$11,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$140$66,990103 claims
Novo NordiskOzempic, Rybelsus$155$57,08264 claims
PfizerEliquis$144$53,37169 claims
AstraZenecaFarxiga, Breztri Aerosphere$135$39,50857 claims
AbbVieVraylar, Linzess$133$30,95733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Chewelah

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →